Back to News
Market Impact: 0.3

Qualcomm vs. Taiwan Semiconductor Manufacturing: Which Technology Stock Is a Better Buy in 2026?

Source: The Motley Fool

Artificial IntelligenceTechnology & InnovationCorporate EarningsCompany FundamentalsAnalyst InsightsGeopolitics & War

TSMC reported FY2025 revenue of $121.3B, up 33%, and net income of $54.7B, with a 45.1% net margin; its five-year average revenue growth was 24%, and operating margin reached 55.8%. Qualcomm’s FY2025 revenue rose about 13.7% to $44.3B, but its current operating margin was 23.5%, a five-year low, amid higher manufacturing and supply-chain costs. Qualcomm trades at 18.2x forward P/E and 4.4x sales versus TSMC at 28.0x and 17.5x, respectively; the article favors TSMC for growth and profitability while noting its Taiwan geopolitical exposure and Qualcomm’s customer-concentration risks.

Analysis

This is an exposure-choice story, not a clean valuation comparison: TSM monetizes leading-edge capacity across customers, while QCOM’s economics remain more exposed to handset sockets and licensing. If AI infrastructure demand persists, TSM can benefit from customer capex even when individual chip designers gain or lose share; the offset is that its premium embeds continued execution, high utilization, and geopolitical continuity. A slowdown or customer inventory digestion would hit a capital-intensive foundry through utilization and expectations, potentially compressing its multiple before reported earnings turn.

QCOM’s discount may be justified by handset concentration and customer insourcing, but its licensing and connectivity businesses could cushion device-cycle volatility. The article’s claim that more expensive “memory chips” are pressuring QCOM margins needs verification: QCOM is not a memory-chip supplier, so do not treat that attribution as established. Likewise, the Amazon custom-chip partnership is an option, not yet evidence of material revenue or margin contribution; verify contract scope and ramp.

Near term, sentiment favors TSM, but a relative long-TSM/short-QCOM risks becoming an unhedged AI-duration and Taiwan-geopolitics bet. Over 1–3 months, track TSM utilization/capex and customer orders, plus QCOM handset-chip demand, licensing trends, and margin guidance. Over 6–18 months, AI-driven capacity demand supports TSM structurally, while QCOM’s diversification must demonstrate scale. Falsifiers: TSM order or utilization deterioration, capex rising faster than monetized demand, a material Taiwan risk premium, or QCOM showing sustained margin recovery and non-handset revenue conversion.

AllMind Terminal

AI-powered research, real-time alerts, and portfolio analytics for institutional investors.

Request Trial

Market Sentiment

Overall Sentiment

mildly positive

Sentiment Score

0.25

Ticker Sentiment

AAPL-0.20
AMZN0.30
AVGO-0.10
NVDA-0.10
NXPI-0.10
QCOM-0.35
TSM0.70

Key Decisions for Investors

  • Avoid buying TSM solely on the article’s growth narrative; initiate only on a pullback or after evidence that customer demand and utilization support the capacity build. Keep position sizing below a typical broad-market semiconductor allocation because Taiwan risk is discontinuous.
  • For a relative-value expression, consider a small, beta-aware long TSM / short QCOM position, not a standalone pair trade at equal dollars. Enter after checking current valuation, borrow, and correlation; reduce or exit if TSM utilization/orders weaken or QCOM reports sustained margin improvement and credible diversification.
  • Treat QCOM as a value-and-cash-generation watch rather than a near-term AI beneficiary until Amazon-related revenue, contribution margins, and timing are independently confirmed. Reassess on its next guidance and handset customer design-win disclosures.
  • Verify the source’s fiscal-year revenue figures and its attribution of memory-cost pressure to QCOM before using either in estimates; the article contains potentially inconsistent scopes and does not establish the claimed cost mechanism.

More News

From AllMind Research

Browse all research